Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy

References

• Piano NPV. (PNPV) 2012-2014. Gazzetta Ufficiale n.47 (12 March 2012). Ministero della Salute. Available at: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1721_allegato.pdf.
   Google Scholar
• Prevenar® 13, Pfizer Vaccines. Summary of product characteristic (20 December 2011). European Medicines Agency (EMA). Available at: http://www.ema.europa.eu.
   Google Scholar
• World Health Organization (WHO). Vaccine introduction guidelines. Adding a vaccine to the national immunization programme. Decision and implementation. 2005. Available at: http://whqlibdoc.who.int/hq/2005/WHO_IVB_05.18.pdf.
   Google Scholar
• Istituto Superiore di Sanità. Dati di sorveglianza delle malattie batteriche invasive aggiornati al 24 febbraio 2012. Available at: http://www.simi.iss.it/files/Report_MBI.pdf.
   Google Scholar
• European Medicines Agency. Science Medicines Health. Assessment report Prevenar 13 pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed). CHMP variation assessment report Type II variation EMEA/H/C/001104/II/0028. Efficacy Study Results. 2011. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001104/WC500119784.pdf.
   Google Scholar
• Standaert B, Demarteau N, Talbird S, Mauskopf J. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?. Vaccine 2010; 28:Suppl 6 G30 - 8; http://dx.doi.org/10.1016/j.vaccine.2010.06.015; PMID: 21075268
   PubMedGoogle Scholar
• Mauskopf J. Meeting the NICE requirements: a Markov model approach. Value Health 2000; 3:287 - 93; http://dx.doi.org/10.1046/j.1524-4733.2000.34006.x; PMID: 16464193
   PubMedGoogle Scholar
• Mauskopf J. Prevalence-based economic evaluation. Value Health 1998; 1:251 - 9; http://dx.doi.org/10.1046/j.1524-4733.1998.140251.x; PMID: 16674550
   PubMedGoogle Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al, Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32 - 41; http://dx.doi.org/10.1086/648593; PMID: 19947881
   PubMed Web of Science ®Google Scholar
• Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006; 295:1668 - 74; http://dx.doi.org/10.1001/jama.295.14.1668; PMID: 16609088
   PubMed Web of Science ®Google Scholar
• Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis 2006; 42:907 - 14; http://dx.doi.org/10.1086/500941; PMID: 16511752
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep 2010; 59:253 - 7; PMID: 20224541
   PubMedGoogle Scholar
• Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010; 14:e197 - 209; http://dx.doi.org/10.1016/j.ijid.2009.05.010; PMID: 19700359
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408 - 16; http://dx.doi.org/10.1093/infdis/jis212; PMID: 22457293
   PubMed Web of Science ®Google Scholar
• Capri S, Bamfi F, Marocco A, Demarteau N. Impatto clinico ed economico della vaccinazione anti-HPV. Int J Public Health 2007; 4:S36 - 54
   Google Scholar
• Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378 - 83; PMID: 18990781
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011; 29:9127 - 31; http://dx.doi.org/10.1016/j.vaccine.2011.09.112; PMID: 21983361
   PubMed Web of Science ®Google Scholar
• Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 2009; 27:4891 - 904; http://dx.doi.org/10.1016/j.vaccine.2009.05.061; PMID: 19520205
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. [Erratum in: Clin Infect Dis. 2008 May 1;46] [9] [:1488. Schmöele-Thoma, B ] [corrected to Schmöle-Thoma, B] Clin Infect Dis 2008; 46:1015 - 23; http://dx.doi.org/10.1086/529142; PMID: 18444818
   PubMed Web of Science ®Google Scholar
• Popolazione residente al 1 Gennaio 2011 per età, sesso e stato civile. Demo.istat. Demografia in cifre. Istituto Nazionale di Statistica. Available at: http://demo.istat.it.
   Google Scholar
• Viegi G, Pistelli R, Cazzola M, Falcone F, Cerveri I, Rossi A, et al. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir Med 2006; 100:46 - 55; http://dx.doi.org/10.1016/j.rmed.2005.04.013; PMID: 16046113
   PubMed Web of Science ®Google Scholar
• Bewick T, Sheppard C, Greenwood S, Slack M, Trotter C, George R, et al. Serotype prevalence in adults hospitalized with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012; 67:540 - 5; http://dx.doi.org/10.1136/thoraxjnl-2011-201092; PMID: 22374921
   PubMed Web of Science ®Google Scholar
• Merito M, Giorgi Rossi P, Mantovani J, Curtale F, Borgia P, Guasticchi G. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy. Vaccine 2007; 25:458 - 65; http://dx.doi.org/10.1016/j.vaccine.2006.08.005; PMID: 17049685
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther 2010; 32:1517 - 32; http://dx.doi.org/10.1016/j.clinthera.2010.06.016; PMID: 20728764
   PubMed Web of Science ®Google Scholar
• Schito GC, Fadda G, Nicoletti G, Debbia EA. Streptococcus pneumoniae isolati da malattie invasive e infezioni respiratorie in soggetti adulti e anziani (>50 anni) ospedalizzati in Italia: studio clinico-microbiologico retrospettivo. Giornale Italiano di Microbiologia Medica Odontoiatrica e Clinica 2011; 15:75 - 98
   Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al, Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187 - 95; http://dx.doi.org/10.1097/00006454-200003000-00003; PMID: 10749457
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21:810 - 5; http://dx.doi.org/10.1097/00006454-200209000-00005; PMID: 12352800
   PubMed Web of Science ®Google Scholar
• Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138:960 - 8; PMID: 12809452
   PubMed Web of Science ®Google Scholar
• Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D, Ortqvist A, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000; 31:444 - 50; http://dx.doi.org/10.1086/313977; PMID: 10987703
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307:804 - 12; http://dx.doi.org/10.1001/jama.2012.169; PMID: 22357831
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; CD000422; PMID: 18253977
   PubMedGoogle Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. [Erratum in: CMAJ. 2009 May 12;180] [10] CMAJ 2009; 180:48 - 58; http://dx.doi.org/10.1503/cmaj.080734; PMID: 19124790
   PubMed Web of Science ®Google Scholar
• Agenzia Nazionale per i Servizi Sanitari Regionali. (Age.na.s.). Ricoveri ospedalieri, i sistemi tariffari regionali vigenti nell’anno 2009. Available at: http://www.agenas.it/index.htm.
   Google Scholar
• Potena A, Simoni M, Cellini M, Cartabellotta A, Ballerin L, Piattella M, et al. Management of community-acquired pneumonia by trained family general practitioners. Int J Tuberc Lung Dis 2008; 12:19 - 25; PMID: 18173872
   PubMed Web of Science ®Google Scholar
• Speranza di vita alla nascita e a 65 anni, per sesso e regione – Anni 2008-2011. Demo.istat. Demografia in cifre. Istituto Nazionale di Statistica. Available at: http://demo.istat.it.
   Google Scholar
• Giusti M, Banfi F, Perrone F, Pitrelli A, Pippo L, Giuliani L. [Community-acquired pneumonia: a budget impact model]. Infez Med 2010; 18:143 - 53; PMID: 20956869
   PubMedGoogle Scholar
• File TM Jr.. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004; 117:Suppl 3A 39S - 50S; PMID: 15360096
   PubMed Web of Science ®Google Scholar
• Lazzaro C, Iori I, Gussoni G. Studio FASTCAP sulla gestione ospedaliera delle polmoniti acquisite in comunità: valutazione farmacoeconomica della fase prospettica. FASTCAP study on the management of hospitalizes patients with community-acquired pneumonia: pharmacoeconomic analysis of the prospective phase. Italian Journal of Medicine 2008; 2:55 - 66
   Google Scholar